Skip to main content
Clinical Trials/NCT06336785
NCT06336785
Completed
Phase 4

A Prospective Clinical Trial Evaluating the "Kiss and Smile HIT" (Holistic Individualized Treatment) Algorithm

Erevna Innovations Inc.1 site in 1 country24 target enrollmentNovember 2, 2023
ConditionsAesthetic

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Aesthetic
Sponsor
Erevna Innovations Inc.
Enrollment
24
Locations
1
Primary Endpoint
Global Aesthetic Improvement Scale (GAIS)
Status
Completed
Last Updated
last year

Overview

Brief Summary

The "Holistic Individualized Treatment" (HIT) approach is used to identify treatment priorities, focus areas, and appropriate products for soft tissue filler treatments.

The "Kiss and Smile HIT" considers lip volume, lip framing and expression to improve patients appearance. This trial will assess the effectiveness of the Kiss and Smile HIT algorithm in treating patients with different kiss and smile related issues (e.g. volume loss, lips lack proper framing, lack of a confident smile due to issues with expression).

Registry
clinicaltrials.gov
Start Date
November 2, 2023
End Date
December 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects must voluntarily sign and date an informed consent, including the photography addendum allowing unrestricted use of photographs for the use of marketing and educational purposes, approved by an independent ethics committee, prior to the initiation of any screening or study-specific procedures.
  • Subjects must at least 18 years old
  • Male or female
  • Subjects must be willing and able to comply with procedures required in the protocol
  • Subjects must be in good health as per investigator's judgment based on medical history
  • Female subjects of child-bearing potential must have a negative urine pregnancy test prior to any dose of study product
  • Female subjects of childbearing potential must practice at least 1 protocol-specified method of birth control that is effective from Baseline through at least 30 days after the last dose or until the end of study, whichever is longer. Female subjects of nonchildbearing potential do not need to use birth control.

Exclusion Criteria

  • Uncontrolled systemic disease
  • Subjects do not present with or have a history of any medical condition that may place the subject at increased risk following exposure to hyaluronic acid or interfere with the study evaluation, including:
  • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
  • History of facial nerve palsy
  • Infection or dermatological condition at the treatment injection sites
  • Marked facial dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or excessively photodamaged skin
  • History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study medical device
  • History of an allergic reaction or significant sensitivity to constituents of the study medical device (or its excipients)
  • Subject has tattoos, jewelry, or clothing which obscure temporal region and cannot be removed
  • Subject has anticipated need for surgery or overnight hospitalization during the study.

Outcomes

Primary Outcomes

Global Aesthetic Improvement Scale (GAIS)

Time Frame: Baseline to Week 2, Week 4, Week 8, Week 20

Frequency of subjects having at least "improved" (e.g., "improved", "much improved" or "very much improved") on the Global Aesthetics Improvement Scale (GAIS), as graded by a blinded evaluator. Grading value varies from worse (grading of -1) to very much improved (grading of 3).

Study Sites (1)

Loading locations...

Similar Trials